Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JEFFREY G WEISS

Allopathic & Osteopathic Physicians Allergy & Immunology Allergy

NPI
1366625162
CMS profile
16368
Location
RIVERDALE, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$37,036.08

129 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 129 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JEFFREY G WEISS

NPI 1366625162 · CMS profile ID 16368

Allopathic & Osteopathic Physicians / Allergy & Immunology / Allergy

RIVERDALE, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 129 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1366625162?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JEFFREY G WEISS, NPI 1366625162, CMS profile ID 16368. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 129 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1366625162?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). JEFFREY G WEISS, NPI 1366625162, CMS profile ID 16368. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 129 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1366625162?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
JEFFREY G WEISS, NPI 1366625162, CMS profile ID 16368, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 129 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1366625162?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

129 matching records · $37,036.08 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 129 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 129.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $14.0710/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829455865 CMS
AstraZeneca Pharmaceuticals LP $12.6310/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829319953 CMS
Optinose US, Inc. $14.7210/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851680741 CMS
GlaxoSmithKline, LLC. $14.9809/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802201687 CMS
GlaxoSmithKline, LLC. $14.0509/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802828843 CMS
AstraZeneca Pharmaceuticals LP $1,400.0009/26/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829739431 CMS
GlaxoSmithKline, LLC. $13.0909/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 801915257 CMS
CSL Behring $1.0909/22/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820230841 CMS
CSL Behring $1.3009/22/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820230847 CMS
CSL Behring $18.0609/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820230907 CMS
Takeda Pharmaceuticals U.S.A., Inc. $14.9909/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820331311 CMS
PFIZER INC. $14.9409/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832782725 CMS
kaleo, Inc. $12.3209/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832129625 CMS
Novartis Pharmaceuticals Corporation $14.2009/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813356623 CMS
AstraZeneca Pharmaceuticals LP $1,050.0009/08/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829855909 CMS
GlaxoSmithKline, LLC. $5.4509/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802707415 CMS
CSL Behring $1.0909/01/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820230825 CMS
ADMA BioManufacturing LLC $22.8608/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 779194079 CMS
GlaxoSmithKline, LLC. $14.9608/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802839391 CMS
AstraZeneca Pharmaceuticals LP $950.0008/24/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829880509 CMS
GlaxoSmithKline, LLC. $1,800.0008/24/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802964105 CMS
GlaxoSmithKline, LLC. $9.2108/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 801622667 CMS
Covis Pharma GmBH $12.3608/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 844399049 CMS
Covis Pharma GmBH $12.3608/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 847693315 CMS
GENZYME CORPORATION $15.0008/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843550783 CMS
GlaxoSmithKline, LLC. $15.0008/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802974013 CMS
Takeda Pharmaceuticals U.S.A., Inc. $14.9608/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820331307 CMS
Octapharma USA, Inc. $17.4207/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812976531 CMS
Takeda Pharmaceuticals U.S.A., Inc. $603.7507/13/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820331303 CMS
CSL Behring $1.3007/07/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820230795 CMS
CSL Behring $35.5407/07/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820230801 CMS
CSL Behring $1.0907/07/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820230807 CMS
CSL Behring $15.7807/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820230889 CMS
AstraZeneca Pharmaceuticals LP $1,850.0006/28/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829488831 CMS
CSL Behring $35.5406/28/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820230813 CMS
kaleo, Inc. $11.9806/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832129623 CMS
AstraZeneca Pharmaceuticals LP $31.9206/24/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829290475 CMS
AstraZeneca Pharmaceuticals LP $109.4006/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829649819 CMS
PFIZER INC. $14.2606/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833284531 CMS
GlaxoSmithKline, LLC. $14.9806/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802201497 CMS
GlaxoSmithKline, LLC. $21.5506/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802977693 CMS
GlaxoSmithKline, LLC. $11.1906/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802694889 CMS
CSL Behring $1.0906/09/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820230783 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1.7506/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820331295 CMS
Takeda Pharmaceuticals U.S.A., Inc. $25.6906/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820331299 CMS
Genentech USA, Inc. $16.2406/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835924340 CMS
AstraZeneca Pharmaceuticals LP $1,850.0005/27/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829474987 CMS
CSL Behring $1.0905/27/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820230771 CMS
CSL Behring $1.6505/27/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820230777 CMS
GlaxoSmithKline, LLC. $13.3905/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802539619 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $13,754.92 27
PY2020 $9,970.82 15
PY2021 $37,036.08 129
PY2022 $72,439.85 241
PY2023 $117,442.80 275
PY2024 $144,104.32 318
PY2025 $137,678.02 337

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $208,524.26 31
PY2024 Principal investigator $46,643.30 12
PY2023 Principal investigator $47,548.66 10

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

31 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $100.00 12/25/2025 Non-covered Recipient Entity
Empirican PRN Inc Dba Circuit Clinical
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 IN ADULT PARTICIPANTS WITH INADEQUATELY CONTROLLED MODERATETOSEVERE ASTHMA No dispute reported 06/30/2026 1228733409
Principal investigator 1 AstraZeneca UK Limited $3,791.00 10/22/2025 Non-covered Recipient Entity
CIRCUIT CLINICAL
a twelfeweek randomized doubleblind phase four study evaluating the effect of airsupra compared to albuterol administered as needed on changes in airway inflammation symptoms and rescue therapy utilization in adults with mild asthma darwin No dispute reported 06/30/2026 1185547817
Principal investigator 1 Novartis Pharmaceuticals Corporation $216.78 10/08/2025 Non-covered Recipient Entity
IMPACT MEDICAL
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190311193
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 09/24/2025 Non-covered Recipient Entity
EMPIRICAN PRN INC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192162995
Principal investigator 1 GlaxoSmithKline, LLC. $500.00 09/12/2025 Non-covered Recipient Entity
EMPIRICAN PRN INC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192166710
Principal investigator 1 GlaxoSmithKline, LLC. $500.00 09/03/2025 Non-covered Recipient Entity
EMPIRICAN PRN INC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192166701
Principal investigator 1 PFIZER INC. $9,000.00 08/02/2025 Non-covered Recipient Entity
Empirican PRN Inc Dba Circuit Clinical
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 IN ADULT PARTICIPANTS WITH INADEQUATELY CONTROLLED MODERATETOSEVERE ASTHMA No dispute reported 06/30/2026 1228723112
Principal investigator 1 Novartis Pharmaceuticals Corporation $17,320.50 08/01/2025 Non-covered Recipient Entity
IMPACT MEDICAL
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190311195
Principal investigator 1 GlaxoSmithKline, LLC. $500.00 06/10/2025 Non-covered Recipient Entity
EMPIRICAN PRN INC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192166366
Principal investigator 1 GlaxoSmithKline, LLC. $500.00 06/10/2025 Non-covered Recipient Entity
EMPIRICAN PRN INC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192169900
Principal investigator 1 GlaxoSmithKline, LLC. $5,649.00 06/06/2025 Non-covered Recipient Entity
EMPIRICAN PRN INC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192163000
Principal investigator 1 GlaxoSmithKline, LLC. $1,562.00 06/06/2025 Non-covered Recipient Entity
EMPIRICAN PRN INC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192163004
Principal investigator 1 GlaxoSmithKline, LLC. $500.00 06/05/2025 Non-covered Recipient Entity
EMPIRICAN PRN INC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192166370
Principal investigator 1 PFIZER INC. $15,042.00 06/05/2025 Non-covered Recipient Entity
Empirican PRN Inc Dba Circuit Clinical
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 IN ADULT PARTICIPANTS WITH INADEQUATELY CONTROLLED MODERATETOSEVERE ASTHMA No dispute reported 06/30/2026 1228791748
Principal investigator 1 GlaxoSmithKline, LLC. $3,844.44 05/26/2025 Non-covered Recipient Entity
EMPIRICAN PRN INC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192166684
Principal investigator 1 AstraZeneca UK Limited $20,050.00 05/21/2025 Non-covered Recipient Entity
CIRCUIT CLINICAL
a randomized,double blind,multicenter,parallel group,phase IIIb 52 week study evaluating the efficacy and safety of PT027 compared with PT007 administered as needed in participants 12 to under 18 years of age with asthma ACADIA No dispute reported 06/30/2026 1185547815
Principal investigator 1 GlaxoSmithKline, LLC. $235.64 04/28/2025 Non-covered Recipient Entity
EMPIRICAN PRN INC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192166358
Principal investigator 1 GlaxoSmithKline, LLC. $235.64 04/28/2025 Non-covered Recipient Entity
EMPIRICAN PRN INC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192166383
Principal investigator 1 GlaxoSmithKline, LLC. $5,487.60 04/09/2025 Non-covered Recipient Entity
EMPIRICAN PRN INC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192166362
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 04/08/2025 Non-covered Recipient Entity
EMPIRICAN PRN INC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192169905
Principal investigator 1 GlaxoSmithKline, LLC. $1,287.80 03/21/2025 Non-covered Recipient Entity
EMPIRICAN PRN INC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192166352
Principal investigator 1 GlaxoSmithKline, LLC. $500.00 03/21/2025 Non-covered Recipient Entity
EMPIRICAN PRN INC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192166379
Principal investigator 1 GlaxoSmithKline, LLC. $4,029.58 03/07/2025 Non-covered Recipient Entity
EMPIRICAN PRN INC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192169908
Principal investigator 1 GlaxoSmithKline, LLC. $500.00 02/24/2025 Non-covered Recipient Entity
EMPIRICAN PRN INC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192166679
Principal investigator 1 GlaxoSmithKline, LLC. $16,731.35 02/24/2025 Non-covered Recipient Entity
EMPIRICAN PRN INC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192166693
Principal investigator 1 GlaxoSmithKline, LLC. $12,750.00 02/05/2025 Non-covered Recipient Entity
EMPIRICAN PRN INC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192166375
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 02/05/2025 Non-covered Recipient Entity
EMPIRICAN PRN INC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192166688
Principal investigator 1 GlaxoSmithKline, LLC. $2,571.00 02/05/2025 Non-covered Recipient Entity
EMPIRICAN PRN INC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192166697
Principal investigator 1 AstraZeneca Pharmaceuticals LP $21,686.00 01/29/2025 Non-covered Recipient Entity
CIRCUIT CLINICAL
Levante A Phase 2b Randomised Double Blind Placebo Controlled Dose Range Finding Study to Assess Efficacy and Safety of Multiple Dose Levels of Inhaled AZD8630 No dispute reported 06/30/2026 1185547813
Principal investigator 1 AstraZeneca Pharmaceuticals LP $52,116.00 01/13/2025 Non-covered Recipient Entity
CIRCUIT CLINICAL
a twelfeweek randomized doubleblind phase four study evaluating the effect of airsupra compared to albuterol administered as needed on changes in airway inflammation symptoms and rescue therapy utilization in adults with mild asthma darwin No dispute reported 06/30/2026 1185547811
Principal investigator 1 GlaxoSmithKline, LLC. $7,317.93 01/09/2025 Non-covered Recipient Entity
EMPIRICAN PRN INC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192166705

Ownership and Investment Interests

One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together

Program yearMeasureAmountRecords
PY2025 Amount invested $1,255.38 1
PY2025 Value of interest $1,255.38 1
PY2024 Amount invested $1,255.38 1
PY2024 Value of interest $1,255.38 1

Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.

Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.

Ownership and Investment Interests records

Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them

2 records · PY2024–2025

Ownership and Investment Interests records (CSV)

Program yearCompanyAmount invested Value of interestTerms of interestInterest held by Dispute statusPublishedRecord ID
PY2025 Consortium of Independent Immunology Clinics, LLC $1,255.38 $1,255.38 n/a Physician Covered Recipient No dispute reported 06/30/2026 1228171715
PY2024 Consortium of Independent Immunology Clinics, LLC $1,255.38 $1,255.38 n/a Physician Covered Recipient No dispute reported 06/30/2026 1147104462